Myfortic and Myelodysplastic syndrome - a phase IV clinical study of FDA data

Summary:

Myelodysplastic syndrome is found among people who take Myfortic, especially for people who are male, 50-59 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Myfortic and have Myelodysplastic syndrome. It is created by eHealthMe based on reports of 11,825 people who have side effects when taking Myfortic from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Dec, 07, 2022

11,825 people reported to have side effects when taking Myfortic.
Among them, 11 people (0.09%) have Myelodysplastic syndrome.

What is Myfortic?

Myfortic has active ingredients of mycophenolic acid. It is often used in kidney transplant. eHealthMe is studying from 11,936 Myfortic users for its effectiveness, alternative drugs and more.

What is Myelodysplastic syndrome?

Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged) is found to be associated with 1,355 drugs and 1,000 conditions by eHealthMe.

Number of Myfortic and Myelodysplastic syndrome reports submitted per year:

Could Myfortic cause Myelodysplastic syndrome?

Time on Myfortic when people have Myelodysplastic syndrome *:

Gender of people who have Myelodysplastic syndrome when taking Myfortic *:

female: 18.18 %
male: 81.82 %

Age of people who have Myelodysplastic syndrome when taking Myfortic *:

Common drugs people take besides Myfortic *:

Common side effects people have besides Myelodysplastic syndrome *:

Anaemia (lack of blood): 5 people, 45.45%
Therapeutic Embolisation: 5 people, 45.45%
Fever: 5 people, 45.45%
Leukopenia (less number of white blood cells in blood): 5 people, 45.45%
Bone Marrow Disorder: 5 people, 45.45%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 5 people, 45.45%
Haemolytic Anaemia (anaemia due to haemolysis): 5 people, 45.45%
Antiphospholipid Syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss): 5 people, 45.45%
Thrombotic Microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury): 5 people, 45.45%
Perianal Abscess: 4 people, 36.36%

Common conditions people have *:

Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 9.09%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 9.09%
High Blood Pressure: 1 person, 9.09%
Hepatitis C: 1 person, 9.09%
Colitis (inflammation of colon): 1 person, 9.09%
Anaemia (lack of blood): 1 person, 9.09%
Abdominal Discomfort: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Myfortic and have Myelodysplastic syndrome?

Check whether Myelodysplastic syndrome is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Onder H, Arsava EM, Arat A, Topcuoglu MA, "Acute middle cerebral artery occlusion treated by thrombectomy in a patient with myelodysplastic syndrome and severe thrombocytopenia", Journal of vascular and interventional neurology, 2015 Jan .

Related studies

How severe was Myelodysplastic syndrome and when was it recovered:

Myelodysplastic syndrome in Myfortic

Expand to all the drugs that have ingredients of mycophenolic acid:

Myelodysplastic syndrome and drugs with ingredients of mycophenolic acid

Alternative drugs to, pros and cons of Myfortic:

Myfortic (11,936 reports)

Common Myfortic side effects:

Browse all side effects of Myfortic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Myelodysplastic syndrome treatments and more:

Myelodysplastic syndrome (54,640 reports)

COVID vaccines that are related to Myelodysplastic syndrome:

Common drugs associated with Myelodysplastic syndrome:

How the study uses the data?

The study uses data from the FDA. It is based on mycophenolic acid (the active ingredients of Myfortic) and Myfortic (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.